DiGeorge Syndrome Critical Region Gene 8 (DGCR8) (N-Term) Peptid
DGCR8
Reaktivität: Human
Wirt: Synthetic
BP, WB, IHC
Produktnummer ABIN975746
Kurzübersicht für DiGeorge Syndrome Critical Region Gene 8 (DGCR8) (N-Term) Peptid (ABIN975746)
Target
DGCR8
(DiGeorge Syndrome Critical Region Gene 8 (DGCR8))
Spezies
Human
Quelle
Synthetic
Applikation
Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
-
-
Protein Region
- N-Term
-
Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-DGCR8 antibody (Catalog #: ARP40984_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Aufreinigung
- Purified
-
-
-
-
Applikationshinweise
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Konzentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handhabung
- Avoid repeated freeze-thaw cycles.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- DGCR8 (DiGeorge Syndrome Critical Region Gene 8 (DGCR8))
-
Hintergrund
-
DGCR8 contains 2 DRBM (double-stranded RNA-binding) domains and 1 WW domain. It may play a part in the etiology of the velocardiofacial/DiGeorge syndrome (VCFS/DGS), a developmental disorder characterized by structural and functional palate anomalies, conotruncal cardiac malformations, immunodeficiency, hypocalcemia, and typical facial anomalies.
Alias Symbols: C22orf12, DGCRK6, Gy1, pasha
Protein Interaction Partner: RNASEN,RNASEN,RNASEN
Protein Size: 773 -
Molekulargewicht
- 85 kDa
-
Gen-ID
- 54487
-
NCBI Accession
- NM_022720, NP_073557
-
UniProt
- Q8WYQ5
Target
-
Sie sind hier:
